News 4 Investigates: How a major retailer was making personal information easily accessible

Posted on November 1, 2018 by Pharmaciststeve

News 4 Investigates: How a major retailer was making personal information easily accessible

https://www.kmov.com/news/news-investigates-how-a-major-retailer-was-making-personal-information/article_7f98db9c-dbe0-11e8-a0a3-fbc413d0ede0.html

ST. LOUIS (KMOV.com) – A major retailer was putting you at risk by making very personal information easily accessible.

Now a News 4 Investigation is getting results and a popular chain that you likely shop at all the time is making changes.

The retailer is Walgreens.

Lawsuit: Wrong Walgreens prescription led to suicide attempt
(Credit: AP Images)

If you enter your number at the cash register, you can earn Balance Rewards from Walgreens, points that can total up to cash.

Recently, though, Trey Forester, from St. Charles County, made a startling discovery.

“It’s just ridiculous to me,” he said.

On the Walgreens website, you could enter in anyone’s phone number, and, if they’re a member of the rewards program, you could see exactly what they bought, when, where and for how much.

“You just need their phone number. It’s simple. Just a phone number,” Forester said.

Forester looked up a few friends.

“I didn’t tell him, but he had bought Rogaine. That’s not information you want people knowing,” Forester said.

News 4 took the issue to consumer experts who say it’s a huge breach of privacy.

“It’s really crazy,” said Cara Spencer.

Spencer works for the Consumer’s Council of Missouri and is also an elected official.

“For me, my phone number is public, that’s true of almost anyone these days,” she said.

Spencer says our purchases say a lot about what’s going on with us, items like itch cream, lice shampoo or adult diapers for example.

“It may be something you wouldn’t want your employer to see, friends or neighbors to know that you’re experiencing some sort of medical situation,” she said.

Or personal items, like pregnancy tests and condoms, could show an ex you’re moving on.

“If you are having a domestic situation, this could wind up putting you in real danger,” she said.

She says nothing about the balance rewards program made it clear that your data might be out there.

“Do you think it should change?” asked Investigative Reporter, Lauren Trager.

“Absolutely, I don’t think this should be so freely and readily available to the general public,” Spencer said.

Forester says he never got a sufficient response and he wanted answers.

“Are they going to fix the problem? Are they going to apologize for allowing this to happen?” he asked.

So News 4 took the issue directly to Walgreens corporate offices and that’s exactly what they did.

Less than two days after our inquiry about it, the website changed.

A spokesperson politely declined to do an interview. But they provided the following statement:

We take the privacy and security of our Balance Rewards members seriously. A recent enhancement…. on Walgreens.com inadvertently also allowed the potential viewing of some additional purchase activity associated with that account. We have taken immediate action to correct this issue. We apologize for any inconvenience this may have caused. 

Forester is relieved it’s resolved.

“It’s all we could talk about,” he said.

Walgreens says the issue has gone on since July.

After we brought this to their attention, Walgreens.com now prompts you to put in a password to see your purchase history.

We checked with other retailers, they require the same thing.

Filed under: General Problems | Leave a Comment »

AG Sessions: statistics of number of doses prescribed determined “medical necessity” ?

Posted on October 30, 2018 by Pharmaciststeve

AG Sessions calls for state medical board ‘to be more aggressive’ in opioid crisis

Sessions says medical boards failed to act quickly

https://www.news5cleveland.com/news/local-news/investigations/ag-sessions-calls-for-state-medical-board-to-be-more-aggressive-in-opioid-crisis

WASHINGTON, D.C. – U.S Attorney General Jeff Sessions is calling on state medical boards across the country “to be more aggressive” when investigating and disciplining physicians engaged in overprescribing painkillers that contributed to an opioid crisis that has ravaged Ohio and the nation.

This comes after an exclusive 5 On Your Side investigation, “Prescription for Failure.”

In a rare, one-on-one interview in Sessions’ private conference room at the U.S. Justice Department in Washington, D.C., Sessions sat down with 5 On Your Side Chief Investigator Ron Regan to discuss the impact of the opioid crisis that led to the deaths of 72,000 Americans last year.

As part of our investigation, we reviewed three dozen of the highest profile cases involving pill mills and doctors across Ohio in recent years. We found 1 in 3 doctors had serious disciplinary histories, including felony drug convictions.

Even so, they were able to keep their medical licenses and later went on to be prosecuted for running pills mills across Ohio.

“It went on too long,” Sessions said. “For physicians to prescribe this extraordinarily high number of pills and nobody know about it is hard to believe.

“These medical boards and professional groups need to be more aggressive — I think in many cases they failed to pick up on information that should have been available,” he said.

In response to the opioid crisis, the Justice Department has launched an aggressive campaign to halt the spread of deadly opioids that includes:

  • New strike force to target drug trafficking and violent crime in Cleveland
  • Providing additional federal prosecutors in Ohio and seven other states
  • Awarding $320 million to combat the opioid crisis
  • Joined in a multi-district class action lawsuit against opioid manufacturers and distributors

The Justice Department’s action follows a directive from President Donald Trump who has declared the opioid crisis a “national health emergency.”

On Oct. 24, 2018, News 5 was invited to the White House where President Trump signed sweeping legislation providing $8 billion in funding to curb the opioid crisis.

You can watch the interview with Chief Investigative Reporter Ron Regan and Attorney General Jeff Sessions in the player above.

You need to watch the video on this piece, Session claims that DOJ has “convicted” some 250 physicians and then corrects himself that they are “charged’ some 250 physicians.  Does this suggest that those attorneys in the DOJ will “bend the truth” so bad that they can almost be assured of a conviction and/or they will get a plead agreement because they will charge the physician with a ” boat load” of fabricated charges… just to get the physician to agree to a plea of a few charges.

It would seem like the DOJ is using the number of doses that the prescriber writes as the primary criteria as to determine that the prescriber is writing high number of doses and thus medical necessity could not be met.  Does not look into how many pts are being cared for, the average number of doses/day or even the average number of mgs/day

What the DOJ and other bureaucrats are doing is tantamount to expecting a cardio vascular surgeon to do open heart surgery with a ‘electric knife” … much like the one a person would use to carve a turkey or ham.

Filed under: General Problems | 7 Comments »

OK: prescribers can prescribe as much MME for chronic pain as they want…as long as they don’t show up on monthly top 20 prescribers

Posted on October 30, 2018 by Pharmaciststeve

New opioid law aims to cut down on abuse, but some say it hurts those who need pain medication

https://www.tulsaworld.com/homepagelatest/new-opioid-law-aims-to-cut-down-on-abuse-but/article_3e2688ef-dd99-5275-bd75-c0413e694bd3.html

A state law that takes effect Thursday mandates new prescribing limits for opioids, but some worry it could end up hurting patients who suffer from chronic pain.

Senate Bill 1446 will limit initial opioid prescription terms and require providers to take extra measures when dosages exceed certain thresholds.

The new law has been hailed for its attempt to address opioid abuse in the state.

Oklahoma ranks No. 6 in the nation in opioid prescriptions dispensed per capita, according to the U.S. Centers for Disease Control and Prevention.

“This certainly does have the potential to curb a lot of abuse and even prevent some addiction, let alone help with some of those who might already be addicted, to slowly get them off of some of these medications much sooner than they would without it,” said Mark Woodward, spokesman for the Oklahoma Bureau of Narcotics and Dangerous Drugs Control.

However, state officials have been scrambling in recent weeks to answer questions from doctors, pharmacists and patients about the new law.

“There’s already a lot of confusion about this law,” said Dr. Blake Kelly, a pain management specialist.

One aspect of the new law limits initial opioid prescriptions to treat acute pain to a seven-day supply for patients.

After the initial prescription, a practitioner may issue another seven-day supply of opioid drugs if necessary, following a consultation with the patient.

Patients must enter into a pain management plan with their provider if the second, seven-day supply is exhausted and additional opioids are to be prescribed.

Woodward agreed that the new law has led to some confusion among patients and providers.

“We’ve had some patients who have called and said they have been fired by their physician, because the physician can no longer prescribe the amounts they have previously been prescribing,” Woodward said.

Woodward said face-to-face consultations between the provider and the patient are recommended, but not required, under the new law.

Kelly said he has heard some pharmacists are not filling patient’s prescriptions “because they are saying you can only get a seven-day supply.”

The initial seven-day limit only applies to new patients, Kelly said.

The law also does not apply to patients receiving active treatment of cancer, hospice, palliative care or residents of a long-term care facility.

Woodward said the seven-day limit on an initial opioid prescription could help curb abuses of the powerful, addicting drugs.

“I think it certainly does have the potential, with the seven-day limit, in preventing some people from getting on the path that would lead to addiction,” Woodward said. “Because clearly the longer you are on any kind of prescription opioid the greater the risk.”

Tamera Stewart, a chronic pain sufferer, said the new law began affecting her prior to it becoming law, following a visit to her pain management doctor’s office.

“In April of this year, the PA (physician assistant) walked in and said ‘not because of anything you have done, but I have to reduce your pain medicine in part because of a new law coming out in Oklahoma,’” Stewart said.

Stewart is national administrator of the Facebook group Coalition of 50 States Pain Advocacy Group.

A two-time cancer survivor, Stewart has undergone 13 surgeries.

The 37-year-old said she first tried steroids and other alternative therapies before turning to opioids about 10 years ago to manager her pain.

Stewart, who is also active in the Don’t Punish Pain Oklahoma advocacy group, said she has heard concerns from others who are worried they will lose their pain medications as a result of the law.

“I got involved (in advocacy) when I started hearing about older residents in my community being told they were not going to get their pain medicine,” Stewart said. “Because I am also a pain patient, it scared me.

“People are being literally abandoned by my doctor,” Stewart said.

Woodward confirmed that patients are reporting that their providers have dropped them or cut back their opioid dosages due to language in the law dealing with opioid dosage levels.

The new law requires providers to document and consult with patients when they are prescribed daily opioid dosages that are equivalent to or greater than 100 milligrams of morphine, abbreviated to 100 MME.

Many doctors already consulted with patients and documented when they exceeded the 100 MME dosage levels, Woodward said.

Still the threshold has prompted concerns.

“There’s some misunderstanding by some who think that the law says that you cannot prescribe pain medicine that would be more than 100 morphine equivalent or MME,” Woodward said.

The law clearly says doctors can continue to write as high a dosage as they believe is needed, Woodward said.

Those who do will have to maintain a written policy and engage in informed consent with the patient if they want to prescribe opioids that exceed the 100 MME, Woodward said.

“But there is no restriction that says anywhere that patients have to be at or under 100 morphine equivalent doses,” Woodward said.

Stewart said providers are fearful if they don’t reduce opioid dosages that they prescribe, they could end up on a state list that identifies them as a top prescriber.

“It’s an environment where everybody is afraid to write prescriptions because of the stigma,” Stewart said.

At issue is a list of top 20 prescribers of opioids that is generated monthly by the OBNDD.

The agency has been providing the list for years to state medical regulatory boards, Woodward said.

“That’s some of the concerns we are trying to get physicians to understand, if they are over 100 MME and they are on a list because they are one of the top prescribers, that doesn’t mean they are under investigation,” Woodward said. “It is simply a list that is generated by law.”

Kelly said everyone agrees that opioid dosages need to come down.

“But the concern is if someone is at three, four or five hundred MMEs and we wean them down to the 150 or 200 range and they are suffering, do we continue to wean them down, or is it understandable to leave them there understanding that they are on half the dosage that they were on for 10 years and they are barely able to get off the couch or out of bed at this level,” Kelly said.

“If we take them down lower what kind of quality of life are they going to have?” Kelly asked.

Filed under: General Problems | 2 Comments »

Untreated pain may cause high blood pressure.. HBP medication may cause cancer

Posted on October 30, 2018 by Pharmaciststeve

Common Blood Pressure Medication Linked To Increased Risk Of Lung Cancer

https://www.forbes.com/sites/robertglatter/2018/10/27/common-blood-pressure-medication-linked-to-increased-risk-of-lung-cancer/#410f621c7b4e

Based on results of an observational study published earlier this week in The BMJ, angiotensin-converting-enzyme (ACE) inhibitors were associated with an increased risk of lung cancer, compared with a similar, but distinct type of blood pressure medication known as angiotensin-receptor blockers (ARBs).

Lisinopril, molecular model. Drug of the angiotensin-converting enzyme (ACE) inhibitor class used to treat hypertension, congestive heart failure and heart attacks. Atoms are represented as spheres and are colour-coded: carbon (grey), hydrogen (white), nitrogen (blue) and oxygen (red). (Courtesy of Getty Images)

Researchers from Boise ENT evaluated patients from a U.K. primary care database and identified over 900,000 adults who began treatment with any type of blood pressure medication from 1995 through 2015. They excluded those with any history of cancer.

Over 335,000 patients were treated with ACE inhibitors, 29,000 with ARBs, and 101,000 with both an ACE and ARB inhibitor. Ramipril (26%) was the most common ACE noted in the study, along with lisinopril (12%) and perindopril (7%).

Over a follow-up period of 6 years, lung cancer was diagnosed in 0.8% (7,952) of this 900,000-person cohort. After taking into consideration smoking and other potential confounding factors, ACE inhibitor use was associated with a 14 % greater risk for lung cancer relative to ARB use (1.6 vs. 1.2 per 1000 person-years). In a secondary analysis, use of an ACE inhibitor for less than 5 years was not associated with an elevated risk for lung cancer.

However, the study noted that the elevated risk didn’t become evident until a patient had been on an ACE inhibitor for 5 years , but did increase with greater than 10 years of use (31% increased risk).

YOU MAY ALSO LIKE

In their study, researchers explained that use of ACE inhibitors results in accumulation of bradykinin in the lungs , which “has been reported to stimulate growth of lung cancer.” ACE inhibitor use may also result in elevated levels of a compound known as substance P, produced in lung cancer cells and related to growth of the tumor and its associated blood vessels.

In light of such data, it’s important for the public to understand that this is only an observational study–not a randomized double blind placebo controlled study–making the absolute risk to patients low. But data indicates that ACE inhibitors account for nearly a third of all blood pressure medications prescribed in the UK, making the results a potential concern for a large number of patients.

While ACE inhibitors have been highly effective medications used to treat high blood pressure in the short term, there have been concerns raised about the safety of their long term use, specifically related to elevated risk of lung cancer.

Moreover, observational studies have led to mixed findings (related to actual lung cancer risk vs. overall risk of cancer), with no clear consensus to date, and meta-analyses of randomized controlled trials have not found evidence of elevated cancer risk, due to small sample size and length of follow-up (median of 3.5 years) compromising validity of findings.

Important limitations of the study that should be mentioned include lack of information about socioeconomic status, diet, exposure to asbestos or radon, as well as family history of lung cancer for patients enrolled in the study. The authors also did not have detailed information regarding number of pack-years of smoking, an important risk factor for incidence of lung cancer.

That said, there is biochemical evidence demonstrating a possible association between ACE inhibitor use and risk of lung cancer with elevated levels of bradykinin and substance P that could facilitate growth of lung cancer.

Certainly in any patient at risk for lung cancer, the benefits associated with taking an ACE inhibitor to reduce blood pressure and cardiac risk need to be weighed against risk for  lung cancer.

This view is echoed by one expert who expressed concern about the risks associated with ACE inhibitors.

“This high quality study shows that ACE inhibitors are a risk factor for lung cancer,” said Klaus Lessnau, M.D, a pulmonary and critical care specialist at Lenox Hill Hospital in New York City.

“The most important factor remains smoking, but implies that ACE inhibitors should be contraindicated in smokers and ex-smokers, armed with a study that reveals significant statistical association and biologic plausibility,” offered Lessnau.” “One wonders if they should be continued in nonsmokers,” he added.

As a result, this study is important to highlight based on the large number of patients currently taking long term ACE inhibitors and the inherent concern they may have for elevated cancer risk–and the potential need to change their medication–based on the results of this study.

Again, it’s important to emphasize that this is an observational study and the overall risk to patients is relatively low.  Patients should have a discussion with their health care provider regarding the risks and benefits of remaining on an ACE inhibitor. One option might be to switch to an ARB if there is ongoing concern, since there has been no elevated risk of lung cancer observed thus far with this class of antihypertensives .  ARBs may, in fact, reduce risk of lung cancer with a protective effect, based on recent studies.

In an accompanying editorial in BMJ, Dr. Deirdre Cronin-Fenton, Associate Professor, Department of Clinical Epidemiology, Aarhus University in Denmark places validity in the findings, but recommends the need for ongoing and further studies to validate the findings of this prospective observational cohort study.

In her editorial, Cronin-Fenton writes the study “highlights the value of registry data and a ‘big data’ approach to evaluating long term outcomes, which may be challenging to investigate in clinical trials. Although a 14% relative increase in lung cancer incidence might not translate to a large absolute risk, the findings are important given the considerable use of ACEIs worldwide.”

Cronin-Fenton continues:  “Nonetheless, in an individual patient, concerns about the long term risk of lung cancer should be balanced against gains in life expectancy associated with use of ACEIs. As [the authors] point out, further studies with long term follow-up are now needed to enhance the scientific evidence on the long term safety of these drugs.”

ACE inhibitors certainly have been beneficial in controlling blood pressure in the clinical setting. While this study highlights a biochemical mechanism that does exist, the data still is observational in nature, and will require more in-depth study to definitively make a determination regarding the decision to discontinue and replacing it in favor of a new class of medications for managing blood pressure

Filed under: General Problems | Leave a Comment »

AG Sessions is reviving the US government’s out-of-date, ineffective, and counterproductive war on drugs

Posted on October 30, 2018 by Pharmaciststeve

US Revives its Harmful Drug War

Attorney General Sessions to Crack Down on Marijuana

https://www.hrw.org/news/2018/01/04/us-revives-its-harmful-drug-war

US Attorney General Jeff Sessions is reviving the US government’s out-of-date, ineffective, and counterproductive war on drugs. Today it was reported that he will rescind the 2013 Cole Memo, which allowed federal prosecutors to choose not to prosecute marijuana offenses in the states that allow adults to consume it.

U.S. Attorney General Jeff Sessions delivers remarks on the U.S. system for asylum-seekers at the Executive Office for Immigration Review in Falls Church, Virginia, U.S. October 12, 2017.

Expand
U.S. Attorney General Jeff Sessions delivers remarks on the U.S. system for asylum-seekers at the Executive Office for Immigration Review in Falls Church, Virginia, U.S. October 12, 2017. © 2017 Reuters

Last year, Sessions also reinvigorated the war on drugs by rescinding former Attorney General Eric Holder’s Smart on Crime guidance to keep low-level, nonviolent offenders out of prison, and repealed then-President Barack Obama’s 21st Century Policing practices, put in place to curb excessive drug law enforcement.

Earlier this week, California became the sixth US state to allow recreational use of marijuana for adults. Sessions’ latest action shows that the attorney general wants federal prosecutors to have much less leeway in deciding whether to enforce federal marijuana laws in states like California. At a moment when preliminary US Centers for Disease Control data suggests that 146 people are dying every day in the United States from opioid overdoses, it is difficult to understand why the White House is focusing such energy on marijuana policy. President Donald Trump has yet to nominate directors for either the Drug Enforcement Administration or the Office of National Drug Control Policy.

Sessions’ combined actions will fuel arrests and mass incarceration in states and at the federal level. Every 25 seconds, someone in the United States is arrested for merely possessing drugs.

One in nine arrests at the state level is for drug possession – 1.25 million arrests every year – and they all cycle through the criminal justice system. Human Rights Watch has documented that this massive effort has had negligible impact on drug availability, and has even worsened the harms of drug trafficking and drug dependence. Even though African Americans and whites use drugs at the same rates, African Americans are disproportionately targeted, arrested, and incarcerated for drug offenses. Those incarcerated for drug offenses typically do not have access to drug treatment and can carry a scarlet letter for years, which impedes successful reentry into society by limiting housing and employment options.

Make no mistake, the war on drugs is again underway. It’s now up to Congress to check the Justice Department’s misguided policies by passing legislation to decriminalize possession for personal use of marijuana and other drugs.

Filed under: General Problems | 1 Comment »

Could denial of Rx filling be considered the same as a mis-fill ?

Posted on October 30, 2018 by Pharmaciststeve

The scenario use to go like this…  the patient goes to a physician’s office … the physician exams the pt and if appropriate … writes one or more prescriptions to treat the pt’s acute or chronic disease issues.  The pt went to the pharmacy of their choice to get the medication(s) that their physician determined would treat/manage/resolve their health issues.

The Pharmacist would check the new medication(s) against pt’s current list of medications for other drug interaction(s) , pt potential for known potentially allergies and the new medications, would also verify that the dose for the new medication(s) is within FDA guidelines..

If anything shows up as a potential problem… the pharmacist would reach out to the prescriber to share his/her concerns and – if necessary – make any changes the prescriber may wish to the prescribed medications so that the pt leaves the pharmacy with the appropriate medications to treat their health issues.

In some instances, the prescriber may state  “dispense as I wrote them”, the pharmacist would make notes on the prescription about their concern(s) and dispense the medication(s) to the pt.

In very rare incidents, the Pharmacist will flat out refuse to fill the prescriptions because the problems are TOO GREAT to do otherwise. In my nearly 50 yrs as a licensed Pharmacists I cannot remember any incidents that I flat out refused to fill a prescription..  unless it was forged, altered or got a ” bad PMP report”  Everything a Pharmacist does is based on FACTS !

With 4 + billion prescriptions filled each year in our country… there are going to be some misfills (mistakes)… so the pt walks away without the medication that the prescriber intended for them to have for their health issues.

Within the last 5-10 yrs, many Pharmacists have been told or adopted the authority to refuse to fill a particular prescription for “ANY REASON”. For many years, they were telling pts that “they were not comfortable”… apparently “uncomfortable” has now become a FACT as a reason not to fill a prescription. Over the last few years, Pharmacists apparently have realized that “uncomfortable” was indeed NOT A FACT …so the common reason for refusal to fill is “OUT OF STOCK”.. that is either a FACT or a LIE !

But like the misfill … the pt leaves the pharmacy without the medication that the pt’s prescriber wanted them to be on to treat their health issues.

A misfill is typically a accident whereas a denial of care is INTENTIONAL…  should there be legal consequences for both ?

US Drug Watchdog Now Urges Consumers Who Were Given the Wrong Prescription or Someone Else’s Prescription at a Local Pharmacy to Call About Possible Financial Rewards – Did You Keep the Pills?

https://www.prnewswire.com/news-releases/us-drug-watchdog-now-urges-consumers-who-were-given-the-wrong-prescription-or-someone-elses-prescription-at-a-local-pharmacy-to-call-about-possible-financial-rewards—did-you-keep-the-pills-300740090.html

WASHINGTON, Oct. 30, 2018 /PRNewswire/ — The US Drug Watchdog says, “We are appealing to individuals who was given a totally wrong prescription or another person’s prescription medication by a local pharmacy to call us anytime at 866-714-6466. If a person receives the wrong medical prescription, a prescription with an incorrect dosage, or someone else’s prescription—the medical complications could be extremely serious, or the side effects could be lethal.

“If you were given a completely incorrect medication or someone else’s prescription did you keep the medication, or keep the sales receipt that indicates the error? We would like to help you get compensated if you received the wrong medication at a local pharmacy and you were harmed because of it. However, to make compensation possible we will need proof of the mistake.

“Our effort also includes identifying a parent in any state who was given a prescription for someone else rather than their child or their child’s prescription was not the correct medication, or the dosage was not correct.” http://USDrugWatchdog.Com

The US Drug Watchdog’s Pharmacy Errors initiative is nationwide and is focused on identifying consumers in any state who were injured because a local pharmacy gave them the prescription for someone else – or filled a prescription with the wrong medication.  The group is now urging consumer in all states such as California, New York, Illinois, Florida, Texas,  Ohio, New Jersey, Nebraska, Louisiana, Nevada, Minnesota, Georgia, Tennessee, Washington, Alaska, Missouri, Pennsylvania or any other state to carefully look at the prescription they are picking up at a pharmacy to ensure it really is what their physician had prescribed. 

For more information, victims of pharmacy medication errors can call the US Drug Watchdog anytime at 866-714-6466. http://USDrugWatchdog.Com

The US Drug Watchdog is warning possible severe health side effects of a pharmacy medication errors include:

  • Death (example a consumer with a severe heart condition is mistakenly given antibiotics. Some antibiotics can cause arrhythmia with a person with serious heart issues.)
  • Hospitalization (example a pharmacist mistakenly gives a pregnant woman an epilepsy drug, the anticoagulant, or a drug to treat bipolar disorder). These types of drugs have all been linked to severe birth defects.
  • Allergic reactions or a person having a severe reaction that could cause hospitalization.
  • In most instances pharmacy prescription errors are caused by, labeling errors, mix-ups with another patient’s order, dispensing the wrong drug or wrong dosage, incompatible health conditions or adverse interactions with other medications.

The US Drug Watchdog says, “If you possess proof your pharmacy gave you the wrong prescription or someone else’s prescription, please call us anytime at 866-714-6466 – especially if you were injured by the mistake. We want to make certain you get compensated. However, as mentioned we will need proof of the mistake either being you still are in possession of the incorrect prescription, or your sales receipt indicates the error.” http://USDrugWatchdog.Com

Media Contact:

Thomas Martin

800-714-0303

SOURCE US Drug Watchdog

Related Links

http://USDrugWatchdog.Com

Filed under: General Problems | 1 Comment »

mme’s “morphine milligram equivalent” and Titration tonight 10/30/2018

Posted on October 30, 2018 by Pharmaciststeve

Tonight on
The Doctor’s Corner w/ hosts
Dr. Kline & Jonelle Elgaway
8pm est

Topic:
mme’s “morphine milligram equivalent”
and Titration

Call into the studio line (415) 915-2291.
You can listen to tonight’s program on our website:
www.cawnation.com
Click “Listen”
Or
YouTube Channel “The Doctor’s Corner”
Direct link is:
https://www.youtube.com/channel/UCQk7ewfPvTfo3pleSzvth7A

Filed under: General Problems | 1 Comment »

Time to move your prescription business to a independent pharmacy ?

Posted on October 30, 2018 by Pharmaciststeve

Investors are more interested in their ability to make a profit than the potential of chronic pain pts being denied appropriate therapy.  Notice that they are using the 49,000 opiate deaths – of which the majority  – and growing – are from illegal opiates from Mexico and China.

This article suggests that the major chain pharmacies are going to get the same message from these investors activists Investors for Opioid Accountability

Also note that they reference ALLEGATIONS by the DEA against Rite Aid dispensing controlled substances with using a medical practitioner’s incorrect or invalid DEA registration number. It appears that this was an ADMINISTRATIVE ISSUE – a BOOKKEEPING ERROR- … of submitting a INCORRECT or INVALID DEA number of the prescriber… not that the prescriber did not have the legal authority to prescriber controlled substances.  This could easily happen in entering a new prescriber to the computer’s database, causing all prescriptions submitted going forward to have the incorrect number until the error was discovered.  It is not typical for the Rx dept staff to check and recheck a prescriber’s DEA number in the computer system each time a new or refill prescription is handled.  This appears to be just another “money grab” by the DEA… if they have illegally dispensed controlled substances the fine would have been in the multi-million area.

If these investor groups are more concerned about their profits from the stocks they own in these and other pharmacy chains and/or companies that have prescription depts as part of their operation. They are apparently using claimed opiate deaths using both legal & illegal opiates… so they are not apparently looking for the “real numbers” they only “real numbers that they are interested in  is those that shows up on their balance sheet.

Click here to use a website that will help you find a INDEPENDENT PHARMACY by zip code. The typical independent pharmacy where you will be dealing with the Pharmacist/Owner and the how you are treated is typically the difference if like night and day .. if you have been patronizing a chain store.  We had our own independent pharmacy for 20 yrs..  I am very familiar with the mindset.

Is it time to show all those outside interests that are trying to adversely impact your chronic pain therapy ? Move all your prescriptions to a INDEPENDENT PHARMACY and show them just how important your patronage of these chains stores is to the company’s stock price and bottom line

 

Amid mounting lawsuits alleging inadequate oversight of opioid dispensing, investors back calls for a board risk assessment at Rite Aid annual meeting

https://www.iccr.org/amid-mounting-lawsuits-alleging-inadequate-oversight-opioid-dispensing-investors-back-calls-board

At Rite Aid’s annual meeting of shareholders earlier today, 56.7% of investors supported a shareholder resolution calling for a board report describing how the company is monitoring and managing financial and reputational risks related to the opioid crisis.

Provisional estimates from the National Institute on Drug Abuse (NIDA) indicate opioid deaths rose to 49,000 in 2017 and a recent report pegged the cumulative economic toll of the opioid epidemic at over $1 trillion.

The resolution was filed by the UAW Retiree Benefits Trust as part of an ongoing campaign by Investors for Opioid Accountability (IOA), a coalition of institutional investors representing over $2.2 trillion in assets that have been engaging companies related to opioids to encourage governance reforms that will address the problem. An earlier engagement initiated by the Teamsters with McKesson resulted in the first board report on risks tied to opioids. Last year similar resolutions achieved the support of a majority of independent investors at manufacturers and distributors AmerisourceBergen and Depomed and were withdrawn in advance of a vote at Cardinal Health and Endo when they agreed to publish board risk reports.

Rite Aid is the first of three retail pharmacies that will receive board risk resolutions for their 2018-2019 proxy. Resolutions will also be filed at Walgreens and CVS.

“Retail pharmacies that are dispensing these drugs to patients on a daily basis can play an important role in preventing their misuse,” said Donna Meyer of Mercy Investment Services, and co-leader of the IOA. “It is critical that these companies have robust monitoring and management mechanisms in place to thwart potential fraud and to avoid the legal and financial liabilities associated with the improper distribution and misuse of these medicines.”

Rite Aid has already been the subject of numerous lawsuits related to opioid distribution. The company is a defendant in the Ohio multidistrict opioid litigation. Separately, a lawsuit by several municipalities in West Virginia alleging that Rite Aid’s inadequate oversight of its distribution of opioids contributed to the epidemic in that state was also moved to federal court in April 2018. According to its annual report, Rite Aid also faces similar lawsuits in Tennessee and South Carolina.

Rite Aid has also come under fire recently from the Drug Enforcement Administration (DEA) for irresponsible dispensing and distribution of controlled substances. In 2017, Rite Aid settled claims, according to an announcement by the DEA,

“to resolve allegations that certain Rite Aid pharmacies in Los Angeles dispensed and/or recorded controlled substances using a medical practitioner’s incorrect or invalid DEA registration number”.  Rite Aid paid an $834,200 civil penalty.

A separate resolution calling on Rite Aid to produce a sustainability report detailing the company’s environmental, social and governance risk achieved 77% support, again a clear indication that shareholders believe a focus on ESG performance would greatly benefit investors.

Both resolutions secured the endorsement of proxy advisory services Glass Lewis and ISS.

“Beyond the misuse of opioids, Rite Aid is woefully behind its peers in addressing many environmental and social challenges,” said Tom McCaney of the Sisters of St. Francis of Philadelphia. “A glaring example of the conflict between its stated mission and day-to-day operations is Rite Aid’s continued sales of tobacco products. If your mission is ‘to improve the health and wellness of our communities…’ you have no business selling tobacco. A comprehensive sustainability report reflecting a company-wide policy would assist Rite Aid in eliminating these conflicts.”

The investors say they look forward to productive dialogues with management on these issues in the coming months.

About the Interfaith Center on Corporate Responsibility (ICCR)
Celebrating its 48th year, ICCR is the pioneer coalition of shareholder advocates who view the management of their investments as a catalyst for social change. Its 300 member organizations comprise faith communities, socially responsible asset managers, unions, pensions, NGOs and other socially responsible investors with combined assets of over $400 billion. ICCR members engage hundreds of corporations annually in an effort to foster greater corporate accountability. www.iccr.org

Filed under: General Problems | 3 Comments »

The group seeks to localize key recommendations from the National Institutes of Health’s National Pain Strategy in the Golden State

Posted on October 29, 2018 by Pharmaciststeve

Survey: 100 Chronic Pain Patients Needed

Survey: 100 Chronic Pain Patients Needed

www.nationalpainreport.com/survey-100-chronic-pain-patients-needed-8837619.html

When over 100 California thought-leaders and luminaries in pain management (physicians, payers, administrators, policy makers, etc.) gather in Los Angeles November 2nd to develop a California Pain Strategy, they need some guidance.

That’s why they are asking the National Pain Report readers to help shape the discussion.

The group seeks to localize key recommendations from the National Institutes of Health’s National Pain Strategy in the Golden State. Then they hope that this strategy cannot only be implemented in California, but it will be a guide for other states.

To do that, they must understand what the chronic pain community thinks the big issues are.

To do that, they are asking for our readers to complete a short survey.

Please do that here.

Also, understand that if you try to fill out the survey and it won’t let you, it means we have reached the 100 persons limit the California leaders have asked.

If you want to add your opinion in the commentary section, please do. We are interested in your comment always, but especially on the topic of what a real comprehensive pain strategy should look like.

It’s easy to say, we need more access to pain medication—and many of you will (understandably).

But what else should be done around the issues of more physician training, patient and physician education, insurance coverage, alternative treatments and technologies or other issues that matter to you.

We really want to know.

The National Pain Strategy was adopted a couple of years ago, but its implementation has been, quite frankly, very slow in coming.

Many chronic pain physicians, advocates and patients believe the National Pain Strategy is the right recipe for dealing with chronic pain and that efforts to implement it, even at the state level, make good sense for the chronic pain patients and their loved ones.

The idea in California is that the nation’s largest state might be an example for other states and the federal government to follow.

That’s what Friday’s session in Los Angeles is designed to start—or resume:

A real conversation about chronic pain.

Filed under: General Problems | 2 Comments »

What is the difference between patient abandonment and a FIRING SQUAD ? – NOT MUCH ?

Posted on October 29, 2018 by Pharmaciststeve

Until last week, I had a friend who had suffered from Systemic Lupus and a rarer condition known as Durcem’s Disease for over 20 years. Her pain management doctors told her they had to wean her off all of her pain meds because of changing laws. She went to 4 different pain managements clinics to be told they couldn’t help her either. Thursday morning, she took all the pain pills and had left and passed away in her sleep instead of facing life without the pain medications she had taken for over 20 years.

Are there really any really NEW LAWS… is this a classic example of PATIENT ABANDONMENT ?  Should – at least – the first pain clinic be held for ASSISTING  SUICIDE and PATIENT ABANDONMENT ?  Since in our legal system the “value of life” of a person that is handicapped, disabled, elderly, retired, unemployable is about the same as the family pet – NEAR ZERO… if you are no longer a “maker” and if someone does something that harms you.. there is no “financial damage” and thus our legal system sees no legal claim. Actually if a “taker” is pushed out of the system.. there is a “financial gain” to Medicare/Medicaid/SS or the insurance industry.

 

Filed under: General Problems | 6 Comments »

« Previous Page — Next Page »